for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

The Medicines Company

MDCO.O

Latest Trade

54.59USD

Change

-0.00(-0.00%)

Volume

1,669,255

Today's Range

52.31

 - 

54.68

52 Week Range

16.69

 - 

54.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
54.59
Open
52.98
Volume
1,669,255
3M AVG Volume
43.86
Today's High
54.68
Today's Low
52.31
52 Week High
54.68
52 Week Low
16.69
Shares Out (MIL)
79.35
Market Cap (MIL)
4,212.30
Forward P/E
-16.82
Dividend (Yield %)
--

Next Event

Q3 2019 Medicines Co Earnings Release

Latest Developments

More

Medicines Co Announces Positive Topline Results For Orion-10 Phase 3 Study Of Inclisiran In ASCVD Patients

Medicines Co Announces Positive Topline Results For Orion-9 Phase 3 Study Of Inclisiran In Heterozygous Familial Hypercholesterolemia Patients

The Medicines Co Announces Positive Topline Results From First Pivotal Phase 3 Trial Of Inclisiran

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About The Medicines Company

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Industry

Biotechnology & Drugs

Contact Info

8 SYLVAN WAY

+1.973.2906000

http://www.themedicinescompany.com

Executive Leadership

Mark Timney

Chief Executive Officer, Director

Christopher J. Visioli

Chief Financial Officer, Treasurer

Stephen M. Rodin

General Counsel, Secretary

Clive A. Meanwell

Chief Innovation Officer

Alexander J. Denner

Independent Director

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.710

2017

-1.970

2018

-2.720

2019(E)

-3.210
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
110.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2,144.76
LT Debt To Equity (MRQ)
2,144.76
Return on Investment (TTM)
-26.92
Return on Equity (TTM)
-24.64

Latest News

Latest News

BRIEF-Medicines Co Says CEO Clive A. Meanwell's 2017 Total Compensation Was $7.6 Million

* MEDICINES CO SAYS CEO CLIVE A. MEANWELL'S 2017 TOTAL COMPENSATION WAS $7.6 MILLION VERSUS $6.7 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2KsU3bs Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-The Medicines Co Reports Q1 GAAP Loss Per Share $1.14 From Continuing Operations

* Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.76 FROM CONTINUING OPERATIONS

BRIEF-The Medicines Company Announces Chief Financial Officer Transition

* THE MEDICINES COMPANY ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION

BRIEF-Medicines Co Says Board Appointed Christopher Visioli As CFO

* MEDICINES - ON MARCH 21, BOARD APPOINTED CHRISTOPHER VISIOLI CFO AND TREASURER OF COMPANY, EFFECTIVE IMMEDIATELY

Medicines Company cuts board size, activist Denner to get more control

Medicines Company on Thursday said it was cutting the number of directors on its board, a move that could give billionaire investor Alex Denner greater control.

BRIEF-The Medicines Company Appoints Sarah Schlesinger To Its Board Of Directors

* THE MEDICINES COMPANY APPOINTS SARAH SCHLESINGER TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations

* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS

BRIEF-The Medicines Company Reaches Enrollment Target For Orion-9 Ahead Of Schedule

* THE MEDICINES COMPANY REACHES ENROLLMENT TARGET FOR ORION-9 AHEAD OF SCHEDULE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics

* THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING Source text: (http://bit.ly/2muRQBT) Further company coverage:

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors

BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company

* Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for...

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

BRIEF-The Medicines Company reports third-quarter 2017 business and financial results

* The Medicines Company reports third-quarter 2017 business and financial results

BRIEF-The Medicines Company announces FDA approval of Vabomere

* The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam)

FDA approves Medicines Co's urinary tract infection drug

The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co's antibacterial drug for patients with complicated urinary tract infections (cUTI).

BRIEF-Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations

* The Medicines Company reports second quarter 2017 business and financial results

BRIEF-The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE

* The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE

BRIEF-Medicines Co says commenced implementation of workforce reduction​

* Medicines Co - on june 1, 2017, Medicines company commenced implementation of a workforce reduction

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up